Search Within

Department of Medicine

Formats
  1. Journal Article (19590)
  2. Meeting Abstract (16038)
  3. Review (1149)
  4. Book Section (934)
  5. Editorial (608)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22319)
  2. Hematologic Malignancies, Division of (13275)
  3. Center for Hematologic Malignancies (11059)
  4. GSK Faculty (10645)
  5. Survivorship Research (9329)
  6. Division of Subspecialty Medicine (7534)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1065)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2110)

More Publishers

Results (39616)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Devimistat results in a low complete remission rate in heavily pre-treated Burkitt lymphoma
    Meeting Abstract

    Steiner, R.; Nikolaenko, L.; Kambhampati, S.; Khan, N.; Nair, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez Rivera, I. I.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genomic characterization and classification of BCL6 rearranged follicular lymphomas
    Meeting Abstract

    Amallraja, A.; Gundem, G.; Domenico, D.; Ossa, J. E. A.; Aypar, U.; Baik, J.; Kluk, M.; Sethi, S.; Lopez, K.; Qualls, D. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Subsequent treatment and clinical outcome following induction therapy on a phase II study of oral azacitidine plus CHOP for peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Ruan, J.; Orlando, E. H.; Moskowitz, A.; Chen, Z.; Mehta-Shah, N.; Sokol, L.; Horwitz, S.; Rutherford, S. C.; Sahni, T.; Melnick, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • North American adult T-cell leukemia lymphoma has frequent mutations in CCR4 and responds in vitro to a small molecule CCR4 antagonist
    Meeting Abstract

    Liu, E.; Verma, A.; Pradhan, K.; Shah, U. A.; Shastri, A.; Guillen, E.; Sica, A.; Lauvau, G.; Janakiram, M.; Kassner, P. D.
    Blood (2024)

    Fulltext@MSK | Save
  • Demographics, characteristics, survival and outcomes in older, untreated, acute myeloid leukemia patients with NPM1 mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
    Meeting Abstract

    Borate, U.; Li Welkie, R.; Huang, Y.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Adult AML patients with NUP98 fusions are frequently therapy-related, and are associated with monocytic differentiation, recurring mutations in NRAS, DNMT3A and WTI and poor outcome
    Meeting Abstract

    Yao, J.; Aypar, U.; Sethi, S.; Boussi, L.; Londono, D.; Sukhadia, P.; Berman, E.; Stein, E. M.; Dogan, A.; Xiao, W.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Venetoclax-based therapy versus intensive chemotherapy followed by allogeneic-stem cell transplantation for high-risk elderly acute myeloid leukemia
    Meeting Abstract

    Iat, A.; Bewersdorf, J. P.; Gilhodes, J.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Bystrom, R. P.; Deangelo, D. J.; Berton, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase i study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies
    Meeting Abstract

    Richter, J.; Thomas, S. K.; Krishnan, A. Y.; Laubach, J. P.; Cohen, A. D.; Trudel, S.; Costa, L. J.; Bahlis, N. J.; Forsberg, P. A.; Kaedbey, R.; more...
    Blood (2024)

    Fulltext@MSK | Save